The metabolic effects of intermittent fasting in patients with type 2 diabetes exist in the short term but disappear after its discontinuation: A systematic review and meta-analysis of randomized controlled trials
Liu F, Zhang Z, Sun W, Li T
Nutrition research (New York, N.Y.) · 4 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2025-04-18 · Nutr Res · vol. 138 · págs. 135–150
- Editorial
- Elsevier BV
- Citado
- 7 citas · más que el 78% de estudios similares · 1.3× el promedio de su campo
- Referencias
- 59 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC-ND
- Áreas de investigación
- Dietary Effects on Health · Diabetes Management and Research · Diet and metabolism studies
- Palabras clave
- intermittent fasting, type 2 diabetes, HbA1c, fasting blood glucose, weight loss, caloric restriction, Mediterranean diet, ad libitum feeding, glycemic control, long-term metabolic effects, glycemic variability, insulin sensitivity, insulin resistance, satiety hormones, gut microbiota
- MeSH
- humans, diabetes mellitus, type 2, blood glucose, fasting, time factors, middle aged, female, male, randomized controlled trials as topic, glycated hemoglobin, intermittent fasting
4 autores
- Fangjun Liu🇨🇳Hebei Medical University
- Zhengxin Zhang🇨🇳Hebei Medical University
- Wenjie Sun🇨🇳Hebei Medical University
- Tao Li🇨🇳 · autor de correspondenciaHebei Medical University
Resumen
El texto original del estudio, en el idioma en que se publicó.
This meta-analysis aimed to determine the short- (< 3 months) and long-term (≥ 3 months) metabolic effects of IF in patients with type 2 diabetes. We hypothesized that IF is non-inferior to other dietary control methods (including continuous energy restriction, standard diet, Mediterranean diet and ad libitum diet) in terms of both short-term and long-term metabolic impacts in patients with type 2 diabetes. We searched for studies in the MEDLINE, EMBASE, and Cochrane Library until August 20, 2023. Studies with non-type 2 diabetes patients, interventions other than IF, no control group, or non-randomized clinical trial designs were excluded. A meta-analysis was then conducted with a random effects model. The Risk of Bias was assessed using the Cochrane risk-of-bias tool (ROB 2). 12 articles with a total of 966 participants were included. IF significantly decreased glycated hemoglobin A1c (HbA1c) (standardized mean difference [SMD]: -0.93; 95% confidence interval [CI]: -1.64, -0.22; P = 0.01), fasting plasma glucose (FPG) (SMD: -0.73; 95% CI: -0.92, -0.54; P < 0.00001) and body weight (SMD: -1.11; 95% CI: -1.92, -0.31; P = 0.007) in the short term compared to control interventions, but showed a similar effect to control interventions in the long term. Substantial heterogeneity existed among our studies. Over the intervention period, long-term IF may safely and feasibly help patients with type 2 diabetes effectively manage blood sugar and reduce body weight, but the metabolic benefits of IF don't endure after its discontinuation. Therefore, continual long-term IF may provide more lasting metabolic benefits.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.